Madcam1-KO Mouse
Common Name
Madcam1-KO
제품 ID
S-KO-03059
Backgroud
C57BL/6NCya
품종 계통계통 ID
KOCMP-17123-Madcam1-B6N-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Madcam1-KO Mouse (카탈로그 번호 S-KO-03059)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Madcam1-KO
품종 계통계통 ID
KOCMP-17123-Madcam1-B6N-VA
유전자명
제품 ID
S-KO-03059
유전자 별칭
MAdCAM-1
배경
C57BL/6NCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 10
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000020554
NCBI 전사체 ID
NM_013591
타겟 영역
Exon 2~4
유효 영역 크기
~1.9 kb
유전자 연구 개요
Madcam1, short for mucosal addressin cell adhesion molecule 1, encodes an immunoglobulin family vascular addressin. It controls lymphocyte homing into intestinal tissues by decorating endothelial cells lining gut post-capillary and high endothelial venules, thus regulating immunity and inflammation. Its expression is directed by an NKX-COUP-TFII morphogenetic code [7].
In cancer, the down-regulation of Madcam1 in the ileum due to post-antibiotic gut recolonization by Enterocloster species drives the emigration of enterotropic α4β7+CD4+ regulatory T 17 cells into the tumor. Genetic deficiency or antibody-mediated neutralization of Madcam1 and its receptor, α4β7 integrin, mimicked the immunosuppressive effects of antibiotics, indicating Madcam1's role in cancer immunosurveillance [1].
In colitis, optogenetic activation of local colonic sympathetic innervations attenuated experimental colitis by decreasing endothelial expression of Madcam1, and antibody blockade of Madcam1 abrogated the optogenetic effect on immune cell extravasation and pathology [2].
In acute liver failure, hepatic Madcam1 levels were induced and positively correlated with liver damage. Activating the cholinergic anti-inflammatory pathway downregulated Madcam1 and inhibited gut-derived proinflammatory lymphocytes infiltration [3].
In glaucoma, retinal endothelial cell expression of Madcam1 was elicited by β7+ CD4+ T cells, and neutralization with an Madcam1 antibody ameliorated retinal ganglion cell loss [4].
In Crohn's disease, treatment with anti-TNF-α reduced the number of Madcam1-positive mucosal capillaries [5].
In hepatocellular carcinoma cells, Madcam1 overexpression suppressed, while depletion stimulated doxorubicin-induced apoptosis [6].
In melanoma, knockdown of Madcam1 impeded epithelial-mesenchymal transition and inhibited tumor growth and metastasis [8].
In checkpoint inhibitor colitis, endothelial cells upregulated Madcam1, which may preferentially respond to vedolizumab [9].
In summary, Madcam1 is crucial for lymphocyte homing and immune regulation. Studies using gene knockout or antibody-mediated neutralization models have revealed its significant roles in various disease conditions such as cancer, colitis, liver failure, glaucoma, Crohn's disease, hepatocellular carcinoma, melanoma, and checkpoint inhibitor colitis, providing potential therapeutic targets for these diseases.
References:
1. Fidelle, Marine, Rauber, Conrad, Alves Costa Silva, Carolina, Kroemer, Guido, Zitvogel, Laurence. 2023. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. In Science (New York, N.Y.), 380, eabo2296. doi:10.1126/science.abo2296. https://pubmed.ncbi.nlm.nih.gov/37289890/
2. Schiller, Maya, Azulay-Debby, Hilla, Boshnak, Nadia, Hakim, Fahed, Rolls, Asya. 2021. Optogenetic activation of local colonic sympathetic innervations attenuates colitis by limiting immune cell extravasation. In Immunity, 54, 1022-1036.e8. doi:10.1016/j.immuni.2021.04.007. https://pubmed.ncbi.nlm.nih.gov/33932356/
3. Fu, Shan, Ni, TianZhi, Zhang, MengMeng, Zhao, YingRen, Liu, JinFeng. 2023. Cholinergic Anti-inflammatory Pathway Attenuates Acute Liver Failure Through Inhibiting MAdCAM1/α4β7-mediated Gut-derived Proinflammatory Lymphocytes Accumulation. In Cellular and molecular gastroenterology and hepatology, 17, 199-217. doi:10.1016/j.jcmgh.2023.10.012. https://pubmed.ncbi.nlm.nih.gov/37926366/
4. He, Chong, Xiu, Wenbo, Chen, Qinyuan, Yu, Ling, Lu, Fang. 2023. Gut-licensed β7+ CD4+ T cells contribute to progressive retinal ganglion cell damage in glaucoma. In Science translational medicine, 15, eadg1656. doi:10.1126/scitranslmed.adg1656. https://pubmed.ncbi.nlm.nih.gov/37531415/
5. Younes, Mamoun, DuPont, Andrew W, Cash, Brooks D, Ertan, Atilla. . Alterations in MAdCAM1-Positive Mucosal Capillaries and Integrin a4b7-Positive Lymphocytes in Crohn's Disease Treated with Anti-TNFα Biologics. In Annals of clinical and laboratory science, 51, 678-685. doi:. https://pubmed.ncbi.nlm.nih.gov/34686510/
6. Wang, Jiayi, Ma, Lifang, Tang, Xun, Yu, Yongchun, Sun, Fenyong. . Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells. In Oncotarget, 6, 24075-91. doi:. https://pubmed.ncbi.nlm.nih.gov/26124182/
7. Dinh, Thanh Theresa, Xiang, Menglan, Rajaraman, Anusha, Pan, Junliang, Butcher, Eugene C. 2022. An NKX-COUP-TFII morphogenetic code directs mucosal endothelial addressin expression. In Nature communications, 13, 7448. doi:10.1038/s41467-022-34991-2. https://pubmed.ncbi.nlm.nih.gov/36460642/
8. Tian, Yuan, Guo, Yantong, Zhu, Pei, Li, Guiying, Zhu, Xun. 2019. TRIM59 loss in M2 macrophages promotes melanoma migration and invasion by upregulating MMP-9 and Madcam1. In Aging, 11, 8623-8641. doi:10.18632/aging.102351. https://pubmed.ncbi.nlm.nih.gov/31600735/
9. He, Jun Yan, Kim, Yang-Joon, Mennillo, Elvira, Kattah, Michael G, Oh, David Y. 2024. Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis. In Journal for immunotherapy of cancer, 12, . doi:10.1136/jitc-2023-008628. https://pubmed.ncbi.nlm.nih.gov/38642938/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
